Morgan Stanley Pliant Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,753,613 shares of PLRX stock, worth $5.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,753,613

Previous 3,051,514 23.01%

Holding current value

$5.71 Million

Previous $4.12 Million 5.71%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$1.16 - $1.69 $814,434 - $1.19 Million	702,099 Added 23.01%	3,753,613 $4.35 Million
Q1 2025 May 15, 2025	BUY	$1.35 - $13.53 $3.06 Million - $30.7 Million	2,269,510 Added 290.22%	3,051,514 $4.12 Million
Q4 2024 Feb 14, 2025	SELL	$10.55 - $15.7 $370,505 - $551,368	-35,119 Reduced 4.3%	782,004 $10.3 Million
Q3 2024 May 14, 2025	BUY	$10.52 - $14.35 $1.51 Million - $2.06 Million	143,276 Added 21.26%	817,123 $9.16 Million
Q3 2024 Nov 14, 2024	BUY	$10.52 - $14.35 $1.51 Million - $2.06 Million	143,276 Added 21.26%	817,123 $9.16 Million
Q2 2024 May 14, 2025	SELL	$10.58 - $15.61 $1.14 Million - $1.69 Million	-108,157 Reduced 13.83%	673,847 $7.24 Million
Q2 2024 Oct 17, 2024	BUY	$10.58 - $15.61 $3.07 Million - $4.52 Million	289,745 Added 75.43%	673,847 $7.24 Million
Q2 2024 Aug 14, 2024	BUY	$10.58 - $15.61 $3.07 Million - $4.52 Million	289,745 Added 75.43%	673,847 $7.24 Million
Q1 2024 Oct 17, 2024	SELL	$14.14 - $19.59 $4.1 Million - $5.68 Million	-289,745 Reduced 43.0%	384,102 $5.72 Million
Q1 2024 Aug 16, 2024	SELL	$14.14 - $19.59 $295,822 - $409,842	-20,921 Reduced 5.17%	384,102 $5.72 Million
Q1 2024 May 15, 2024	SELL	$14.14 - $19.59 $295,822 - $409,842	-20,921 Reduced 5.17%	384,102 $5.72 Million
Q4 2023 Aug 16, 2024	SELL	$12.85 - $19.15 $3.45 Million - $5.15 Million	-268,824 Reduced 39.89%	405,023 $7.33 Million
Q4 2023 Feb 13, 2024	BUY	$12.85 - $19.15 $4 Million - $5.96 Million	311,020 Added 330.86%	405,023 $7.33 Million
Q3 2023 Nov 15, 2023	BUY	$14.58 - $20.15 $91,562 - $126,541	6,280 Added 7.16%	94,003 $1.63 Million
Q2 2023 Aug 14, 2023	SELL	$18.12 - $30.56 $3.58 Million - $6.04 Million	-197,741 Reduced 69.27%	87,723 $1.59 Million
Q1 2023 May 15, 2023	BUY	$18.73 - $36.26 $3.21 Million - $6.22 Million	171,484 Added 150.45%	285,464 $7.59 Million
Q4 2022 Feb 14, 2023	SELL	$17.0 - $25.43 $1.7 Million - $2.54 Million	-99,713 Reduced 46.66%	113,980 $2.2 Million
Q3 2022 Nov 14, 2022	SELL	$7.67 - $24.23 $1.09 Million - $3.45 Million	-142,346 Reduced 39.98%	213,693 $4.46 Million
Q2 2022 Oct 27, 2022	BUY	$4.11 - $8.75 $136,760 - $291,156	33,275 Added 10.31%	356,039 $2.85 Million
Q2 2022 Aug 15, 2022	BUY	$4.11 - $8.75 $136,760 - $291,156	33,275 Added 10.31%	356,039 $2.85 Million
Q1 2022 Oct 27, 2022	SELL	$7.01 - $14.1 $233,257 - $469,177	-33,275 Reduced 9.35%	322,764 $2.26 Million
Q1 2022 May 13, 2022	SELL	$7.01 - $14.1 $142,695 - $287,019	-20,356 Reduced 5.93%	322,764 $2.26 Million
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.26 $2.35 Million - $3.5 Million	191,875 Added 126.86%	343,120 $4.63 Million
Q3 2021 Nov 15, 2021	BUY	$16.48 - $28.98 $2.49 Million - $4.38 Million	151,245 New	151,245 $2.55 Million

Others Institutions Holding PLRX

# of Institutions

127

Shares Held

57.7M

Call Options Held

245K

Put Options Held

86.7K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $74M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account